Cardium Therapeutics (CXM)
Cardium Therapeutics Enterprise Value: 19.34M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CXM Enterprise Value Rankings
| Overall | 6th percentile | 3983 of 4266 |
| Sector | 11th percentile | 438 of 493 in Healthcare |
| Industry | 11th percentile | 135 of 153 in Biotechnology |
CXM Enterprise Value Range, Past 5 Years
| Minimum | 5.824M | Jun 2007 |
| Maximum | 103.45M | Dec 2007 |
| Average | 49.34M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
You may also be interested in these CXM related companies
CXM News
$CXM Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System http://stks.co/3yJh
about 4 days ago by OTCShowcase
about 4 days ago by OTCShowcase
Cardium Therapeutics (CXM) Enters Excellagen Agreement with Angel Biomedical
May 15, 9:09AM Street Insider
May 15, 9:09AM Street Insider
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
May 15, 9:00AM PR Newswire
May 15, 9:00AM PR Newswire
$CXM Growing Footprint in Health Sciences and Regenerative Medicine Space http://stks.co/3nJI
about 17 days ago by MissionIR
about 17 days ago by MissionIR
Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System
May 11, 8:20AM Marketwire
May 11, 8:20AM Marketwire
Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
Apr 19, 6:43PM PR Newswire
Apr 19, 6:43PM PR Newswire
Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™
Apr 02, 8:00AM PR Newswire
Apr 02, 8:00AM PR Newswire
Cardium Presents Fourth Quarter and Year-End 2011 Financial Results and Recent Developments
Mar 30, 9:15AM PR Newswire
Mar 30, 9:15AM PR Newswire
FAST Act to Modernize Approval Process -- Cardium and BioSante Poised to Benefit
Mar 19, 8:20AM Marketwire
Mar 19, 8:20AM Marketwire
Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum
Jan 30, 9:00AM PR Newswire
Jan 30, 9:00AM PR Newswire
Biotechnology Industry on the Upswing - BioSante and Cardium Therapeutics Look to Rally
Jan 17, 8:20AM Marketwire
Jan 17, 8:20AM Marketwire
Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
Jan 03, 9:01AM Benzinga
Jan 03, 9:01AM Benzinga
Cardium Therapeutics (CXM) Enters Into Cross-Strategic Equity Investment Partnership with SourceOne Global Partners
Dec 21, 9:23AM Street Insider
Dec 21, 9:23AM Street Insider
$CXM heavy premarket volume, potential FDA approval would be nice way to finish year
about 517 days ago by CaptainOyama
about 517 days ago by CaptainOyama
$SPY trending higher. Check out $CXM FDA approval coming 12/31 this stock trades at .48 will go to $2 or more on approval.
about 522 days ago by scottheggs
about 522 days ago by scottheggs
What to look forward to June 2010 for investors? $CXM, $HNAB, $DCTH, $QCOR http://goo.gl/fb/GuP5p #europecrisis
about 728 days ago by comparebroker
about 728 days ago by comparebroker
$CXM filled the gap.support at .58. first target .87, next stop 1.03. hope to see u all there.
about 766 days ago by StockTA888
about 766 days ago by StockTA888
but will consider buying in the .40s in $CXM, if it gets back down there.
about 768 days ago by LitheLyricist
about 768 days ago by LitheLyricist
buying programs chewing through offers in $CXM. A big offer is left at .55. Risk/reward not good enough to pay .55, probably
about 768 days ago by LitheLyricist
about 768 days ago by LitheLyricist
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CXM | 0.2375 | -0.00 | -0.25% | 28.41M |
| CXH | 10.60 | +0.00 | +0.00% | |
| CXDC | 4.93 | -0.05 | -1.00% | 234.32M |
| CXA | 24.42 | +0.02 | +0.08% | |
| CX | 5.47 | +0.00 | +0.00% | 5.797B |
| CWTR | 0.84 | +0.02 | +2.44% | 102.15M |
| CVS | 44.98 | -0.19 | -0.42% | 58.77B |
| CVRT | 21.71 | +0.00 | +0.00% | |
| CVR | 18.70 | -0.07 | -0.37% | 18.14M |
| CVO | 1.72 | +0.02 | +1.18% | 109.10M |
